Therapeutic options for preventing transplant-related progressive renal and vascular injury

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The first organ transplantation occurred in 1954 in Boston under the direction of Joseph Murray: a kidney removed from a healthy donor and transplanted into his identical twin promptly started to function, and the recipient survived for 9 years. Since then, attempts to suppress the recipient's immune system were pursued with the aim to extend the possibility of transplantation beyond involving identical twins.1 The first approach to suppress the rejection process employing the use of sublethal total-body irradiation combined with cortisone had a poor outcome, however. The rate of successful transplantation of kidneys from cadaveric donors and familial human leukocyte antigen (HLA)-matched living donors slowly increased during the 1960s and early 1970s following the introduction of azathioprine with corticosteroids.1 But a prolonged use of corticosteroids was the cause of high mortality due to excessive immunosuppression. Only the introduction of cyclosporine in 1980 really improved the rate of 1-year graft survival from 70 to more than 80%.2

Original languageEnglish
Title of host publicationVascular Complications in Human Disease: Mechanisms and Consequences
PublisherSpringer London
Pages128-136
Number of pages9
ISBN (Print)9781846289187
DOIs
Publication statusPublished - 2008

    Fingerprint

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Tomasoni, S., & Benigni, A. (2008). Therapeutic options for preventing transplant-related progressive renal and vascular injury. In Vascular Complications in Human Disease: Mechanisms and Consequences (pp. 128-136). Springer London. https://doi.org/10.1007/978-1-84628-919-4_10